Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 3

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: focus on insulin glulisine

Authors Heather Ulrich, Benjamin Snyder, Satish K Garg

Published Date August 2007 Volume 2007:3(3) Pages 245—254

DOI

Published 15 August 2007

Heather Ulrich1,4, Benjamin Snyder1,Satish K Garg1,2,3

1Barbara Davis Center for Childhood Diabetes; 2Department of Medicine; 3Pediatrics; 4Department of Clinical Pharmacy, School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, CO, USA

Abstract: Normalization of blood glucose is essential for the prevention of diabetes mellitus (DM)-related microvascular and macrovascular complications. Despite substantial literature to support the benefits of glucose lowering and clear treatment targets, glycemic control remains suboptimal for most people with DM in the United States. Pharmacokinetic limitations of conventional insulins have been a barrier to achieving treatment targets secondary to adverse effects such as hypoglycemia and weight gain. Recombinant DNA technology has allowed modification of the insulin molecule to produce insulin analogues that overcome these pharmacokinetic limitations. With time action profiles that more closely mimic physiologic insulin secretion, rapid acting insulin analogues (RAAs) reduce post-prandial glucose excursions and hypoglycemia when compared to regular human insulin (RHI). Insulin glulisine (Apidra®) is a rapid-acting insulin analogue created by substituting lysine for asparagine at position B3 and glutamic acid for lysine at position B29 on the B chain of human insulin. The quick absorption of insulin glulisine more closely reproduces physiologic first-phase insulin secretion and its rapid acting profile is maintained across patient subtypes. Clinical trials have demonstrated comparable or greater efficacy of insulin glulisine versus insulin lispro or RHI, respectively. Efficacy is maintained even when insulin glulisine is administered post-meal. In addition, glulisine appears to have a more rapid time action profile compared with insulin lispro across various body mass indexes (BMIs). The safety and tolerability profile of insulin glulisine is also comparable to that of insulin lispro or RHI in type 1 or 2 DM and it has been shown to be as safe and effective when used in a continuous subcutaneous insulin infusion (CSII). In summary, insulin glulisine is a safe, effective, and well tolerated rapid-acting insulin analogue across all BMIs and a worthy option for prandial glucose control in type 1 or 2 DM.

Keywords: glycemic control, glycosylated hemoglobin A1c (HbA1c), rapid-acting insulin analogues, type 1 diabetes mellitus, type 2 diabetes mellitus, insulin glulisine, body mass index (BMI)

Download Article [PDF] 

Readers of this article also read:

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm [Corrigendum]

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:2129-2130

Published Date: 13 June 2013

Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm

Tian XH, Wang ZG, Meng H, Wang YH, Feng W, Wei F, Huang ZC, Lin XN, Ren L

International Journal of Nanomedicine 2013, 8:865-876

Published Date: 27 March 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Critical appraisal of lurasidone in the management of schizophrenia

Caccia S, Pasina L, Nobili A

Neuropsychiatric Disease and Treatment 2012, 8:155-168

Published Date: 17 April 2012

Is age-related macular degeneration a problem in Ibadan, Sub-Saharan Africa?

Oluleye TS

Clinical Ophthalmology 2012, 6:561-564

Published Date: 11 April 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes

Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan

Vascular Health and Risk Management 2010, 6:373-382

Published Date: 18 May 2010

Corneal abrasion

Scott Fraser

Clinical Ophthalmology 2010, 4:387-390

Published Date: 26 April 2010

Potential of liraglutide in the treatment of patients with type 2 diabetes

Carolyn F Deacon

Vascular Health and Risk Management 2009, 5:199-211

Published Date: 2 February 2009

Folic acid: a marker of endothelial function in type 2 diabetes?

Arduino A Mangoni, Roy A Sherwood, Belinda Asonganyi, Emma L Ouldred, Stephen Thomas, Stephen HD Jackson

Vascular Health and Risk Management 2005, 1:79-83

Published Date: 29 January 2005